Lyra Therapeutics, Inc.
LYRA
$7.47
$0.131.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 770.00K | 1.19M | 1.53M | 1.47M | 1.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 770.00K | 1.19M | 1.53M | 1.47M | 1.82M |
| Cost of Revenue | 22.25M | 30.40M | 43.77M | 49.67M | 56.14M |
| Gross Profit | -21.48M | -29.22M | -42.23M | -48.20M | -54.32M |
| SG&A Expenses | 14.31M | 15.95M | 18.50M | 19.25M | 20.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.56M | 46.35M | 62.27M | 68.92M | 76.45M |
| Operating Income | -35.79M | -45.17M | -60.73M | -67.44M | -74.63M |
| Income Before Tax | -38.82M | -79.50M | -93.40M | -97.56M | -101.33M |
| Income Tax Expenses | 19.00K | 29.00K | 39.00K | 50.00K | 59.00K |
| Earnings from Continuing Operations | -38.84 | -79.53 | -93.44 | -97.61 | -101.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.84M | -79.53M | -93.44M | -97.61M | -101.39M |
| EBIT | -35.79M | -45.17M | -60.73M | -67.44M | -74.63M |
| EBITDA | -35.34M | -44.70M | -60.26M | -67.04M | -74.20M |
| EPS Basic | -29.46 | -60.71 | -71.75 | -75.69 | -83.67 |
| Normalized Basic EPS | -16.13 | -20.51 | -27.82 | -31.06 | -37.38 |
| EPS Diluted | -29.46 | -60.71 | -71.75 | -75.69 | -83.67 |
| Normalized Diluted EPS | -16.13 | -20.51 | -27.82 | -31.06 | -37.38 |
| Average Basic Shares Outstanding | 5.28M | 5.24M | 5.21M | 5.13M | 4.74M |
| Average Diluted Shares Outstanding | 5.28M | 5.24M | 5.21M | 5.13M | 4.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |